Will PACS market ever measure up?It has become common practice for many participants in the PACS industry to be generous in superlatives whenever asked to characterize the growth of the PACS market. And finally, it seems there is a good reason
It has become common practice for many participants in the PACS industry to be generous in superlatives whenever asked to characterize the growth of the PACS market. And finally, it seems there is a good reason for it. Customer interest in digital image management seems to be at an all-time high, and vendors are devoting substantial resources, both in marketing and in technology development, to foster that demand.
But is anybody buying? At least one survey, conducted by Technology Marketing Group (see story, page 3), estimates that the U.S. PACS market generated only about $400 million in revenues in 1997, falling short of estimates made by the consulting group just a few years ago. TMG also believes that PACS in the next few years will see only a 5% to 10% growth rate, well off the 20% to 30% growth rates that previously were held as gospel by industry watchers.
On the surface, TMG's new numbers seem to hit the mark. Despite widespread pronunciations last year that the era of filmless radiology was finally at hand, the number of large-scale PACS contracts reported could be counted on the fingers of two hands.
But one thing to remember when evaluating the market is that PACS purchasing can take anywhere from 12 to 24 months, a time period that isn't getting any shorter now that other departments such as IS are increasingly involved in purchasing decisions. While demand for digital image management will continue to grow, the nature of PACS purchasing will likely hold back growth rates in the foreseeable future.
-Erik L. Ridley, Editor
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.